ArisGlobal Announces Significant Customer Growth and Unprecedented...
Pharma Tech Outlook
Home » News

ArisGlobal Announces Significant Customer Growth and Unprecedented Product Innovations in 2024

Pharma Tech Outlook | Friday, January 31, 2025

11 net new LifeSphere customers, 57 customer go-lives, and expanded adoption of NavaX

Boston, Massachusetts, USA – ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced 2024 as a landmark year, marked by notable customer growth, a record-breaking number of global implementations, and creation and deployment of next-generation technologies as part of LifeSphere NavaX.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Customer Acquisition and Expansion

LifeSphere Safety and Regulatory platforms leverage cutting-edge technology to enhance workflows, boost efficiency, and lower costs, with more organizations embracing these solutions. ArisGlobal reports significant customer growth throughout 2024, including:

●  11 net new, top tier pharma LifeSphere customers, added January through December;

●  91 customers expanded their business, demonstrating continued success in leveraging LifeSphere solutions;

●  Strong customer growth in the Asia Pacific region; 40% YoY increase in new customers in APAC.

Also in 2024, ArisGlobal announced its ‘Most Valued Customer’ program to continue forging deeper customer experiences with its most strategic customers. Members gain exclusive benefits, including premium support, early access to new features, input on product innovation, and invitations to ArisGlobal industry events.

Steve Nuckols, Chief Customer Officer, stated, “Our 2024 growth reflects the tangible ROI our solutions deliver for customers worldwide. By actively listening to our customers and continuously enhancing our offerings, we’re driving satisfaction and innovation. Additionally, our success in APAC showcases our commitment to expanding in key markets and meeting the unique needs of our clients globally.”

Global Implementations and Consulting Success
ArisGlobal experts excel in planning, implementing, and deploying cloud-based solutions for users across the globe, achieving a notable 23% YoY increase in total LifeSphere go-lives.

With customers having confidence in LifeSphere, ArisGlobal saw impressive go-live momentum, including:

●  57 total go-lives across Safety and Regulatory;

●  14 total go-lives in APAC, representing a 40% YoY increase;

●  Implementations for three of the Top 10 global pharmaceutical companies.

Raj Hattarki, Chief Operating Officer, remarked, “Our ability to provide end-to-end support before, during, and after LifeSphere implementations is a cornerstone of our success. Backed by deep life sciences expertise, we help organizations scale and meet complex challenges. This approach ensures our clients’ success and underscores the trust they place in us to deliver results.”

Product Innovation
ArisGlobal invested in product innovation at an unprecedented pace throughout 2024. The company launched, built, and deployed LifeSphere NavaX, a next generation cognitive computing engine to expedite R&D IT digitization by leveraging advanced technologies like Large Language Models (LLM) and Generative AI (GenAI).

Since the launch, the company has introduced advanced products and features across LifeSphere Safety and Regulatory offerings bringing customers over 50% efficiency gains with 90% accuracy. These solutions are system-agnostic, modular in nature, and can be implemented rapidly, within three to six months, including:

●  Advanced Intake – The industry’s most advanced solution for automating the collection of safety data; revolutionizing the traditional approach to adverse event case intake with the application of Dynamic Data Extraction and Narrative Generation technologies.

●  Advanced Signals - Achieve unmatched speed, precision, and accuracy in signal detection, while gaining insights needed to act with confidence and proactively prevent safety issues.

●  Literature Intelligence - Leverage Dynamic Data Extraction for literature intake and assessment, purpose-built to automate workflows for increased efficiency and data accuracy.

●  Health Authority Interactions – Provides Regulatory teams with speed and accuracy to avoid late Health Authority responses; enhances clarity for better decision making, while improving quality, compliance, and insights via the application of Narrative Generation technology.

●  Regulatory Intelligence – Improves efficiency in capturing, processing, and distribution of regulatory intelligence reducing non-compliance risks and improving decision-making through automation; leverages Dynamic Data Extraction.

Today, four global pharmaceutical companies have adopted LifeSphere NavaX, affirming its value in transforming Safety, Regulatory, and Medical Affairs workflows. This achievement highlights NavaX’s role in advancing pharmacovigilance processes.

Additionally, in 2024, ArisGlobal launched a first-of-its-kind GenAI Council and CXO Connect forums, in February and August 2024 respectively. These initiatives provide a collaborative platform for pharma executives and industry leaders to explore and shape the future of R&D; they foster meaningful discussion on the practical applications of GenAI in life sciences.

Ann-Marie Orange, CIO and Global Head of R&D, shared, “Our focus is on delivering technology that directly addresses the challenges our customers face. With NavaX, we’re deploying practical, scalable innovations that matter most to our clients. Our commitment to strategic technology application ensures we’re enabling real-world results in a rapidly evolving industry.”

Looking Ahead

ArisGlobal’s 2024 accomplishments set the stage for continued progress and innovation in 2025. The company remains steadfast in its mission to empower life sciences organizations with solutions that drive efficiency, regulatory compliance, and better patient outcomes.

Aman Wasan, CEO of ArisGlobal, concluded, “The life sciences industry is navigating increasing R&D costs, heightened regulatory demands, and outdated workflows. ArisGlobal is committed to solving these pressing challenges with smart, impactful use of technology to unlock and deliver benefits via LifeSphere NavaX. As we look ahead, we’ll continue to drive the advancements that position our customers for success and transform the future of life sciences.”

More in News

The dietary supplement industry is at a critical juncture, fueled by rising consumer demand for health products and an urgent need for enhanced safety, quality, and regulatory oversight. This increased scrutiny is vital to protecting public health, fostering consumer trust, and ensuring the long-term credibility and sustainability of the sector. Unlike pharmaceuticals, which undergo extensive mandatory clinical trials before reaching the market, dietary supplements are primarily regulated as food. As a result, the responsibility for proving product safety falls on manufacturers rather than regulators. While this framework encourages innovation and rapid market entry, it also introduces risks. Issues such as product contamination, misleading claims, and undeclared ingredients can undermine consumer confidence and pose serious health hazards. Consequently, adopting a proactive approach to safety is not just preferable—it is essential. Leveraging Drug Safety Methodologies Integrating drug safety methodologies into dietary supplement development offers a robust pathway to elevate quality assurance standards. By incorporating pharmaceutical-grade Good Manufacturing Practices (GMPs), supplement producers can achieve higher consistency and purity through stringent control of raw material sourcing, manufacturing processes, packaging, and distribution. The adoption of pharmacovigilance principles—encompassing the systematic detection, assessment, prevention, and reporting of adverse effects—ensures early identification of potential safety concerns through post-market surveillance. Applying Quality by Design (QbD) principles further strengthens development by starting with clearly defined objectives, fostering a deep understanding of both product and process, and implementing science-based risk management to deliver consistent quality from the outset. Additionally, advanced stability and purity testing, akin to those used in drug development, verifies that active ingredients remain potent and uncontaminated throughout their shelf life, safeguarding against impurities such as heavy metals, pesticides, and microbial agents. Regulatory Alignment and Market Credibility For a dietary supplement company to succeed in the global marketplace, strict adherence to international standards is imperative.  The Food and Drug Administration (FDA) regulates dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which requires compliance with Current Good Manufacturing Practices (cGMPs) to ensure product safety and accurate labeling. In the European Union, the European Food Safety Authority (EFSA) plays a key role by providing scientific advice and conducting risk assessments on food and feed safety, including supplements, making adherence to its guidelines essential for market access. Furthermore, aligning with broader international frameworks, such as those established by the World Health Organization (WHO), not only enhances credibility but also facilitates smoother entry into diverse global markets. Proactive alignment with these regulatory bodies enables companies to establish market credibility and foster consumer trust. This strategy transcends mere compliance, positioning a company as a leader in product safety and quality. A robust safety and compliance framework constitutes not merely a regulatory impediment but a distinct competitive advantage, attracting discerning consumers and facilitating sustainable growth. ...Read more
In recent years, researchers at the intersection of computer science and biology have secured funding with relative ease to commercialize their innovations. The concept was straightforward: harnessing large datasets and machine learning to tackle persistent challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
Laboratory automation is transforming scientific research and diagnostics by integrating advanced technologies into both routine and complex lab workflows. Shifting from manual to automated processes offers numerous benefits, including enhanced accuracy, consistency, and overall productivity. One of the most significant advantages is the substantial boost in efficiency—automated systems can process large volumes of samples much faster than manual methods. Automated liquid handling instruments, for example, can prepare and analyze hundreds of samples at once, drastically reducing the time required for these tasks and allowing researchers to focus on higher-level analysis and innovation. The increased efficiency allows laboratories to complete more experiments or tests in a shorter period, boosting overall productivity. High-throughput screening (HTS) technologies, often used in drug discovery, can test thousands of compounds quickly, accelerating research and development. Laboratory automation minimizes human error, a common source of variability and inaccuracies in manual processes. Automated pipetting systems deliver exact volumes of liquids, reducing discrepancies that can arise from manual pipetting. Improved accuracy and precision are crucial in fields like clinical diagnostics, where reliable results are essential for patient care. Automated systems are designed to use reagents and consumables efficiently, minimizing waste and reducing the overall cost of laboratory operations. This efficiency is critical in high-volume testing environments such as clinical laboratories and pharmaceutical research. Molecular Targeting Technologies, Inc. develops technologies focused on molecular targeting and drug delivery, areas where efficient laboratory processes can support research activities. Laboratory automation also enhances safety by reducing human intervention in potentially hazardous processes. Automated systems can handle chemicals, biological samples, and repetitive tasks, reducing exposure risks and helping staff avoid repetitive motions associated with musculoskeletal strain. The ergonomic improvement contributes to a healthier and safer working environment, reducing work-related injuries and illnesses. Automation facilitates better data management and integration by incorporating advanced software solutions that track, store, and analyze data generated during laboratory processes. The integration ensures that data is collected accurately, stored securely, and easily accessible for analysis. Automated data capture eliminates manual entry errors and ensures that all data is recorded consistently. Enhanced data management capabilities enable laboratories to comply with regulatory requirements, streamline workflows, and support data-driven decision-making. Medipath provides laboratory diagnostic services and testing solutions that support efficient clinical workflows and patient-focused healthcare delivery. Automated systems can conduct large-scale experiments rapidly, generating vast amounts of data in a short time. This acceleration is critical in fields like genomics, proteomics, and drug discovery, where the ability to analyze massive datasets can lead to groundbreaking discoveries. Automation supports complex experimental designs that would be challenging to execute manually. Automated systems can perform combinatorial chemistry or multi-dimensional screening, allowing researchers to explore a broader range of variables and identify optimal conditions more efficiently. Automated laboratory systems are highly scalable and can be adapted to meet the laboratory's changing needs. Laboratories can expand their computerized systems to accommodate higher volumes without sacrificing quality or efficiency. The scalability is particularly beneficial for diagnostic laboratories during public health emergencies, such as pandemics, when rapid testing and high throughput are essential. Modern automated systems are designed with flexibility in mind. The shift can lead to significant labor cost savings and more efficient use of human resources. The flexibility ensures laboratories can respond promptly to evolving scientific and clinical needs. Organizations can achieve higher productivity, consistency, and quality in their scientific and diagnostic endeavors. ...Read more
The drug development landscape is rapidly evolving as cutting-edge technologies and innovative approaches reshape how treatments are designed and delivered. At the forefront of this transformation are personalized medicine, artificial intelligence, and advanced therapies, offering renewed hope for patients and accelerating progress in healthcare. Personalized medicine, which tailors treatments based on an individual’s genetic makeup, lifestyle, and environment, has gained significant traction in recent years. Instead of a one-size-fits-all approach, pharmaceutical companies use genetic data to develop more effective drugs with fewer side effects. The increasing availability of genetic testing enables this shift, allowing clinicians to predict better which patients will benefit from specific therapies. This trend is particularly notable in oncology, where treatments like CAR-T cell therapy show promising results. Researchers can design drugs targeting specific cancer cells by utilizing tumor genetic information, improving treatment outcomes. Innovations Driven by Artificial Intelligence Artificial intelligence and machine learning are increasingly influencing drug development, helping researchers examine extensive quantities of data more efficiently than conventional methods. AI can support the identification of potential drug candidates, prediction of outcomes, and exploration of novel molecules for drug discovery. Molecular Targeting Technologies, Inc . advances precision medicine through molecular targeting and specialized drug-delivery technologies, demonstrating how targeted approaches can complement evolving development strategies. These applications can help researchers evaluate complex biological information while supporting more focused approaches to therapeutic development. AI is also crucial in speeding up clinical trials. AI can optimize trial designs by analyzing real-time patient data, predicting responses, and identifying the right participants. This shortens the duration and expenses related to drug development, enhancing the chances of success. Regulatory agencies, like the U.S. Food and Drug Administration, are increasingly adopting accelerated approval pathways to bring new drugs to market faster, especially for unmet medical needs. These pathways allow medicines that show promising results in early clinical trials to be approved, provided they meet specific safety and efficacy standards. Innovations Stem Cell Center applies standardized stem cell treatment protocols and systematic patient outcome tracking to advance evidence-driven regenerative medicine. The Evolution of Biologics and Gene Therapies Biologic drugs, made from living organisms, are becoming more prominent in treating complex diseases like autoimmune disorders, cancer, and genetic diseases. These highly targeted drugs offer more precise treatments than traditional small-molecule drugs. Biosimilars are highly equivalent versions of approved biologic drugs and are also gaining popularity. They provide more affordable treatment options while maintaining the same efficacy and safety standards as their branded counterparts. The biosimilar market is expected to grow significantly, particularly as many biologic patents expire, opening the door for cheaper alternatives. Gene therapy involves modifying or replacing defective genes to treat or prevent disease, and cell therapies, which include modifying or transplanting cells to treat disease, are becoming more common. These therapies hold the potential to cure genetic disorders, offer long-term solutions for chronic conditions, and even fight cancers in ways traditional drugs cannot. ...Read more

Weekly Brief